tiprankstipranks
Trending News
More News >
Starpharma Holdings Limited (AU:SPL)
:SPL
Advertisement

Starpharma Holdings Limited (SPL) AI Stock Analysis

Compare
17 Followers

Top Page

AU:SPL

Starpharma Holdings Limited

(OTC:SPL)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 4o)
Rating:51Neutral
Price Target:
AU$0.50
▲(72.41% Upside)
The overall score reflects a challenging financial performance with profitability and cash flow issues, despite strong technical indicators suggesting bullish momentum. Valuation concerns due to negative profitability further impact the score.

Starpharma Holdings Limited (SPL) vs. iShares MSCI Australia ETF (EWA)

Starpharma Holdings Limited Business Overview & Revenue Model

Company DescriptionStarpharma Holdings Limited (SPL) is an Australian biotechnology company focused on the development of innovative drug delivery systems and new therapeutic products. The company specializes in dendrimer technology, which allows for enhanced delivery of drugs and provides unique solutions in various sectors, including pharmaceuticals and personal care. SPL's core products include its proprietary VivaGel, a dendrimer-based gel for the treatment of bacterial vaginosis and prevention of sexually transmitted infections, as well as collaborations in the development of oncology drugs.
How the Company Makes MoneyStarpharma generates revenue primarily through the commercialization of its proprietary products and technology. Key revenue streams include licensing agreements with pharmaceutical companies, royalties from product sales, and development funding from partners for ongoing research and development. The company has established significant partnerships with various global pharmaceutical firms, which provide additional funding and resources for product development. Furthermore, SPL benefits from milestones and royalty payments tied to the successful commercialization of its products, enhancing its earnings potential in the biotech sector.

Starpharma Holdings Limited Financial Statement Overview

Summary
Starpharma Holdings Limited shows potential with revenue growth, but consistent losses impact its financial health. The balance sheet is stable with strong cash reserves, yet negative cash flows indicate operational challenges.
Income Statement
45
Neutral
Starpharma Holdings Limited has shown significant revenue growth with a notable increase in total revenue from the previous year. However, the company continues to report negative net income and EBIT, which impacts its profitability margins. Gross profit margin is relatively high, indicating efficient cost management in production despite overall losses.
Balance Sheet
50
Neutral
The company's balance sheet reflects moderate leverage with a manageable debt-to-equity ratio. The equity ratio indicates a solid capital structure, though a decline in stockholders' equity raises concerns. Cash reserves are strong, providing a buffer against liabilities.
Cash Flow
40
Negative
Operating cash flow remains negative, highlighting cash outflows from operations. While free cash flow has improved slightly, it remains negative, which could strain liquidity. The company has managed capital expenditures well, showing discipline in investment spending.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.85M4.91M8.29M2.94M4.68M1.80M
Gross Profit-3.73M3.69M7.66M1.22M1.91M539.50K
EBITDA-9.72M-10.93M-9.63M-22.08M-22.34M-26.05M
Net Income-9.99M-9.99M-8.16M-15.64M-16.15M-19.73M
Balance Sheet
Total Assets25.42M25.42M36.81M52.09M66.17M73.24M
Cash, Cash Equivalents and Short-Term Investments15.41M15.41M23.36M35.18M49.92M60.50M
Total Debt2.40M2.40M3.53M8.27M8.19M1.17M
Total Liabilities6.42M6.42M8.70M17.27M17.78M10.94M
Stockholders Equity19.00M19.00M28.12M34.81M48.39M62.30M
Cash Flow
Free Cash Flow-6.80M-6.80M-7.07M-14.15M-14.00M-15.05M
Operating Cash Flow-6.76M-6.76M-6.98M-13.53M-13.16M-14.81M
Investing Cash Flow-42.00K-42.00K-89.00K-610.00K-836.00K-246.00K
Financing Cash Flow-1.13M-1.13M-4.75M-695.00K3.23M46.30M

Starpharma Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.29
Price Trends
50DMA
0.22
Positive
100DMA
0.16
Positive
200DMA
0.13
Positive
Market Momentum
MACD
0.03
Negative
RSI
72.38
Negative
STOCH
97.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SPL, the sentiment is Positive. The current price of 0.29 is below the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.22, and above the 200-day MA of 0.13, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 72.38 is Negative, neither overbought nor oversold. The STOCH value of 97.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:SPL.

Starpharma Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AU$44.16M-49.72%10.78%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU$140.11M-41.51%-40.74%-21.21%
AU$88.88M-90.37%26.38%
AU$14.28M-143.71%306.88%
AU$66.49M-138.54%16.61%
AU$27.18M-5.57-157.93%-36.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:SPL
Starpharma Holdings Limited
0.37
0.27
288.30%
AU:CYP
Cynata Therapeutics Limited
0.28
0.05
19.57%
AU:PTX
Prescient Therapeutics Limited
0.05
0.01
25.00%
AU:ILA
Island Pharmaceuticals Ltd
0.40
0.28
233.33%
AU:NOX
Noxopharm Ltd.
0.10
-0.03
-23.08%
AU:AVE
Avecho Biotechnology Limited

Starpharma Holdings Limited Corporate Events

Starpharma Receives $5.5 Million Upfront Payment from Genentech for Oncology Collaboration
Oct 22, 2025

Starpharma Holdings Limited has received an upfront payment of USD $5.5 million from Genentech as part of a recently announced license agreement. This collaboration will utilize Starpharma’s proprietary DEP® platform technology to develop dendrimer-drug conjugates incorporating Genentech medicines for oncology targets. The agreement positions Starpharma to potentially receive up to USD $564 million in development, commercial, and net sales milestones, alongside tiered royalties on global net sales. This partnership enhances Starpharma’s industry positioning by leveraging its advanced dendrimer technology to expand its product offerings and market reach in oncology.

The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.

Starpharma Showcases Strategic Advances in Oncology Drug Delivery
Oct 21, 2025

Starpharma Holdings Limited, a leader in dendrimer technology, presented at the Australian Microcap Investment Conference, highlighting its strategic focus on transforming drug delivery in oncology through its DEP® platform. The company is advancing its pipeline of novel assets, particularly in radiopharmaceuticals, and has secured strategic partnerships with major biotech firms like Genentech and Radiopharm Theranostics. These collaborations underscore the platform’s potential and are expected to expand commercial opportunities significantly. Key developments in the coming year include progressing radiotheranostics to clinical trials, expanding partnerships, and increasing revenue from licensing and product sales.

The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.

Starpharma Director Increases Shareholding
Oct 21, 2025

Starpharma Holdings Limited announced a change in the director’s interest, with Robert B. Thomas acquiring 450,000 ordinary shares through an on-market purchase. This transaction increases his direct holding to 950,000 shares, reflecting a significant personal investment in the company, which could signal confidence in the company’s future prospects.

The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.

Starpharma Announces 2025 AGM with Hybrid Participation
Oct 13, 2025

Starpharma Holdings Limited has announced its 2025 Annual General Meeting, scheduled for November 14, 2025, which will be held in a hybrid format allowing both in-person and remote participation. The Board recommends shareholders vote in favor of all resolutions, emphasizing the importance of shareholder engagement and participation in the company’s strategic decisions.

The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.

Starpharma Director’s Performance Rights Adjusted
Oct 6, 2025

Starpharma Holdings Limited announced a change in the director’s interest notice, revealing that Cheryl Maley, a director, has experienced a lapse of 439,752 performance rights due to unmet performance criteria. This adjustment in director’s interests reflects internal performance evaluations and may impact the company’s governance and stakeholder confidence.

The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.

Radiopharm and Starpharma Collaborate on Novel Cancer Therapy
Sep 30, 2025

Radiopharm Theranostics has entered into a research and option agreement with Starpharma to develop a novel radiopharmaceutical molecule using Starpharma’s DEP® platform. This collaboration marks a significant milestone for both companies, potentially enhancing Radiopharm’s cancer treatment offerings and demonstrating the applicability of Starpharma’s technology in targeted cancer therapies. The agreement includes an exclusive option for Radiopharm to license the developed asset, with significant financial terms tied to successful development and commercialization.

Starpharma Partners with Radiopharm to Develop Novel Radiotherapy Asset
Sep 30, 2025

Starpharma has entered into a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary DEP® platform technology. This partnership is a significant milestone for Starpharma, marking its first radiopharmaceutical collaboration and the advancement of its Star Navigator program into a formal research collaboration. The agreement allows Starpharma to receive R&D service and manufacturing fees, with the potential for substantial financial gains through licensing options, success-based milestones, and royalties. This collaboration highlights the potential of dendrimers in radiopharmaceutical drug development and expands Starpharma’s commercial opportunities without impacting its internal development efforts.

Starpharma Enters Strategic Collaboration with Genentech
Sep 22, 2025

Starpharma Holdings Limited has announced a significant collaboration and license agreement with Genentech, part of the Roche Group. This partnership will leverage Starpharma’s DEP® platform to develop dendrimer-drug conjugates targeting specific oncology areas. The agreement includes an upfront payment of USD $5.5 million, with potential success-based milestones totaling up to USD $564 million. Additionally, Starpharma stands to earn tiered royalties on the global net sales of any resulting products, marking a substantial opportunity for growth and industry positioning.

Starpharma Partners with Genentech to Advance DEP® Cancer Therapies
Sep 22, 2025

Starpharma Holdings Limited has entered into a collaboration and license agreement with Genentech, a Roche Group member, to develop cancer therapies using Starpharma’s DEP® technology. This partnership will see Starpharma receive an upfront payment and potential milestone payments totaling up to USD $564 million, along with royalties on global sales. The collaboration highlights Starpharma’s strategic focus on forming impactful partnerships to expand its market reach and enhance therapeutic offerings, positioning the company strongly within the oncology sector.

Starpharma Announces 2025 Annual General Meeting Details
Sep 17, 2025

Starpharma Holdings Limited announced that its 2025 Annual General Meeting will be held on November 14, 2025, in Melbourne. The announcement highlights the company’s ongoing commitment to transparency and stakeholder engagement, with the Chair’s address and CEO’s presentation to be released to the market prior to the meeting. This meeting is an opportunity for the company to discuss its strategic direction and operational updates, potentially impacting its market positioning and stakeholder relations.

Starpharma Secures $3.7 Million R&D Tax Incentive to Boost Biotechnology Advancements
Aug 28, 2025

Starpharma Holdings Limited has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year under the Australian Federal Government’s program. This incentive is crucial for Starpharma as it continues to invest in high-impact R&D programs, strengthening its position in the global biotechnology sector and supporting the advancement of its dendrimer technology towards commercialization and global patient benefit.

Starpharma Releases 2025 Corporate Governance Statement
Aug 26, 2025

Starpharma Holdings Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability. This release underscores Starpharma’s dedication to maintaining high governance standards, potentially reinforcing stakeholder confidence and supporting its strategic objectives in the competitive biotechnology market.

Starpharma Reports Strong Revenue Growth and Reduced Losses for FY25
Aug 26, 2025

Starpharma Holdings Limited reported a significant increase in revenue for the fiscal year ending June 30, 2025, with a 183% rise to $4.9 million, driven by research revenue and increased sales of Viraleze™ and VivaGel® BV. The company also reduced its reported loss by 31% to $10 million, reflecting decreased research and product development expenditures. These financial results indicate a positive trajectory for Starpharma, enhancing its position in the biotechnology industry and potentially benefiting stakeholders through improved financial performance and strategic growth.

Starpharma’s 2025 Annual Report: Advancing Dendrimer Technology for Better Patient Outcomes
Aug 26, 2025

Starpharma Holdings Limited’s 2025 Annual Report highlights the company’s commitment to delivering meaningful patient outcomes through its advanced dendrimer technology. The report outlines key focus areas including maximizing the value of its DEP® platform, accelerating early asset development, and building long-term sustainability, which are crucial for enhancing the company’s operations and industry positioning.

Starpharma Reports Revenue Decline but Adjusted Growth Amid R&D Investments
Aug 26, 2025

Starpharma Holdings Limited reported a 41% decline in revenue to $4.912 million for the year ending June 30, 2025, compared to the previous year. However, when excluding a one-time settlement from the prior year, adjusted revenue increased by 183%, driven by research revenue from Petalion Therapeutics and increased sales of Viraleze™ and VivaGel® BV. The company’s loss for the period rose by 22% to $9.99 million, though adjusted loss decreased by 32% due to reduced research and product development expenses. The financial results reflect ongoing investment in research and development, particularly in the DEP® drug delivery programs, which are crucial for the company’s strategic growth and industry positioning.

Starpharma Advances DEP® Assets and Expands Global Collaborations
Jul 31, 2025

Starpharma Holdings Limited has made significant strides in maximizing the value of its DEP® assets and expanding its research collaborations. The company has been actively engaging with global stakeholders and showcasing its dendrimer technology at major conventions, while also advancing its radiotheranostics program and preparing for product launches in new markets. Despite challenges such as geopolitical complexities and a shifting oncology landscape, Starpharma remains focused on strategic execution and partnership opportunities to enhance shareholder value and improve patient outcomes.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2025